Chemokines, chemokine receptors and small-molecule antagonists: Recent developments

Trends in Pharmacological Sciences

Volumn 23, Issue 10, 2002, Pages 459-467

  Onuffer, James J ^a   Horuk, Richard ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ALPHA CHEMOKINE; AMD 3389; AZD 7140; AZD 8309; BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CX3C CHEMOKINE; CYCLAM; DPC 168; E 913; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RECEPTOR BLOCKING AGENT; RS 102895; UNCLASSIFIED DRUG; XC CHEMOKINE;

AMINO TERMINAL SEQUENCE; CHROMOSOME; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; LONG QT SYNDROME; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; CHEMOKINES; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, CHEMOKINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036803279     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)02064-3     Document Type: Review

References (59)

1. Flower D.R. Modelling G-protein-coupled receptors for drug design. Biochim. Biophys. Acta. 1422:1999;207-234.
2. Ballesteros J., Palczewski K. G-protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Dev. 4:2001;561-574.
3. Ballesteros J.A., et al. Structural mimicry in G-protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60:2001;1-19.
4. Palczewski K., et al. Crystal structure of rhodopsin: a G-protein-coupled receptor. Science. 289:2000;739-745.
5. International Union of Immunological Societies/World Health Organization . Subcommittee on Chemokine Nomenclature Chemokine/chemokine receptor nomenclature. J. Leukocyte. Biol. 70:2001;465-466.
6. Loetscher P., Clark-Lewis I. Agonistic and antagonistic activities of chemokines. J. Leukoc. Biol. 69:2001;881-884.
7. Loetscher P., et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276:2000;2986-2991.
8. Martinelli R., et al. The CC chemokine eotaxin (CCL11) is a partial agonist of the chemokine receptor CCR2b. J. Biol. Chem. 276:2001;42957-42964.
9. Olgilvie P., et al. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood. 97:2001;1920-1924.
10. Blanpain C., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood. 94:1999;1899-1905.
11. Blanpain C., et al. A chimeric MIP-1α/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J. Leukoyte Biol. 69:2001;977-985.
12. Proudfoot A.E.I., et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271:1996;2599-2603.
13. Proudfoot A.E., et al. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. 274:1999;32478-32485.
14. Elsner J., et al. Differential activation of CC chemokine receptors by AOP-RANTES. J. Biol. Chem. 275:2000;7787-7794.
15. Lambeir A.M., et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276:2001;29839-29845.
16. Vakili J., et al. Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active [9-74] processed variant. J. Immunol. 167:2001;3406-3413.
17. Struyf S., et al. Diverging binding capacities of natural LD78( isoforms of macrophage inflammatory protein-1( to the CC chemokine receptors 1,3, and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur. J. Immunol. 31:2001;2170-2178.
18. Duke-Cohan J.S., et al. Attractin: a cub-family protease involved in T cell-monocyte/macrophage interactions. Adv. Exp. Med. Biol. 477:2000;173-185.
19. De Meester I., et al. CD26, let it cut or cut it down. Immunol. Today. 20:1999;367-375.
20. Van Damme J., et al. The role of CD26/DPP IV in chemokine processing. Chem. Immunol. 72:1999;42-56.
21. Garton K.J., et al. TACE (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276:2001;37993-38001.
22. Hiroyama T., et al. Fractalkine shares signal sequence with TARC: gene structures and expression profiles of two chemokine genes. Genomics. 75:2001;3-5.
23. Forssmann U., et al. Hemofiltrate CC chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15. J. Leukoc. Biol. 70:2001;357-366.
24. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 12:2001;313-335.
25. Baggiolini M. Chemokines in pathology and medicine. J. Intern. Med. 250:2001;91-104.
26. Horuk R., Ng H.P. Chemokine receptor antagonists. Med. Res. Rev. 20:2000;155-168.
27. Luttichau H.R., Schwartz T.W. Validation of chemokine receptors as drug targets. Curr. Opin. Drug Discov. Dev. 3:2000;610-623.
28. Proudfoot A.E.I., et al. The strategy of blocking the chemokine system to combat disease. Immunol. Rev. 177:2000;246-256.
29. Mirzadegan T., et al. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists. Binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275:2000;25562-25571.
30. Dragic T., et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U. S. A. 97:2000;5639-5644.
31. Gerlach L.O., et al. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276:2001;14153-14160.
32. Hatse S., et al. Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharmacol. 60:2001;164-173.
33. Labrosse B., et al. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:1998;6381-6388.
34. Sabroe I., et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. 275:2000;25985-25992.
35. Maeda K., et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 276:2001;35194-35200.
36. Samson M., et al. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J. Biol. Chem. 272:1997;24934-24941.
37. Huang X.C., et al. Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling. Acta Pharmacol. Sin. 21:2000;521-528.
38. Yang J., Liu C.Q. Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120. Acta Pharmacol. Sin. 21:2000;29-34.
39. Liang M., et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur. J. Pharmacol. 389:2000;41-49.
40. Naya A., Saeki T. J-113863. Chemokine CCR1 receptor antagonist. Drugs Future. 26:2001;121-127.
41. Lapierre, D.J.M. (1998) The synthesis and biological evaluation of potent MCP-1 inhibitors. 26th Nat. Med. Chem. Symp. Richmond, VA.
42. Tagat J.R., et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett. 11:2001;2143-2146.
43. Forbes I.T., et al. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. Bioorg. Med. Chem. Lett. 10:2000;1803-1806.
44. Hesselgesser J., et al. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. 273:1998;15687-15692.
45. Cheng S.S., et al. Granulocyte-macrophage colony stimulating factor up-regulates CCR1 in human neutrophils. J. Immunol. 166:2001;1178-1184.
46. Jung S., et al. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:2000;4106-4114.
47. Mack M., et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J. Immunol. 166:2001;4697-4704.
48. Topham P.S., et al. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J. Clin. Invest. 104:1999;1549-1557.
49. Sachais B.S., et al. Molecular basis for the species specificity of the substance P antagonist CP-96,345. J. Biol. Chem. 268:1993;2319-2323.
50. Lee B., et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:1999;9617-9626.
51. Blanpain C., et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell. 13:2002;723-737.
52. Baribaud F., et al. Antigenically distinct conformations of CXCR4. J. Virol. 75:2001;8957-8967.
53. Gupta S.K., et al. Pharmacological evidence for complex and multiple site interaction of CXCR4 with SDF-1(: implications for development of selective CXCR4 antagonists. Immunol. Lett. 78:2001;29-34.
54. Baribaud F., Doms R.W. The impact of chemokine receptor conformational heterogeneity on HIV infection. Cell. Mol. Biol. 47:2001;653-660.
55. Cox M.A., et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell ( chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol. Pharmacol. 59:2001;707-715.
56. Staudinger R., et al. Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope. Biochem. Biophys. Res. Commun. 286:2001;41-47.
57. Esser U., et al. Molecular function of the CD4 D1 domain in coreceptor-mediated entry by HIV type 1. AIDS Res. Hum. Retroviruses. 16:2000;1845-1854.
58. Herrera C., et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J. Biol. Chem. 276:2001;19532-19539.
59. Yokochi S., et al. An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. J. Interferon Cytokine Res. 21:2001;389-398.